Benitec Biopharma Limited

BNTC Healthcare Biotechnology

In the quarter to June 2026, EPS fell 11.3%, free cash flow grew 38.9% and total debt fell 46.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

8.11 0.35 −4.14%
Market cap
$295.1M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
3/9
Altman Z
−66.02
Beneish M
11.02
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
34.00 56.82 67.69 46.95
Net Debt/EBITDA
12.48 13.60 14.10 9.62
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.11) (0.09) (0.08) (0.08)
Book value per Share
3.80 3.71 4.08 2.25
Free Cash Flow
(5.02) (4.47) (3.79) (3.35)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026